Study of antibody levels in a population receiving a booster dose on COVID-19 vaccine

Study on antibody levels after COVID-19 vaccination

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062784

Enrollment

Unknown

Registered

2022-08-18

Start date

2022-08-15

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 vaccine

Interventions

3:a third-dose of Covid-19 vaccine

2:a third-dose of Covid-19 vaccine over six month

3:two-dose of Covid-19 vaccine over six month

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. People over 18 years old; 2. Complete two doses of inactivated COVID-19 vaccine and produce the vaccine from the same manufacturer; 3. People who voluntarily accept antibody testing and sign informed consent; 4. Patients with hypertension who are in good health and well controlled by drugs; 5. Patients with diabetes who are in good health and well controlled by drugs.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Previous infection with novel coronavirus; 3. Any other contraindications to inactivated COVID-19 vaccine vaccination.

Design outcomes

Primary

Measure	Time frame
SARS-cov-2 neutralizing antibody;	—

Countries

China

Contacts

Public ContactZhi Lei

Luzhou Center for Disease Control and Prevention

676111501@qq.com+86 830 2523770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026